eyal

­

About eyal

This author has not yet filled in any details.
So far eyal has created 81 blog entries.

Quark Pharmaceuticals Closes $10 Million Financing SBI Holdings, Inc. CEO Yoshitaka Kitao Appointed to Board. Funds to Support Advancing Clinical Pipeline

June 10th, 2010|

FREMONT, Calif., Jun 10, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the […]

Quark Pharmaceuticals Announces Nature Medicine Publication for Role of RTP801 in Pulmonary Injury and Emphysema

May 17th, 2010|

FREMONT, Calif., May 17, 2010 –  Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the publication of new insights on the role of its proprietary gene target, RTP801, in cigarette smoke-induced pulmonary injury and emphysema. Results are published in the June 2010 edition of Nature Medicine and online in […]

Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO

May 6th, 2010|

FREMONT, Calif., May 6, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale. PF-04523655 is a […]

Quark to Present Data on Predicting Risk of Delayed Graft Function in Kidney Transplant Patients at American Transplant Congress

May 4th, 2010|

FREMONT, Calif., May 4, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the presentation of a poster at the 2010 American Transplant Congress titled, “A Nomogram for Predicting Risk of Delayed Graft Function Following Machine Perfusion of Renal Transplants.” The poster presents a new model developed by William […]

Quark Pharmaceuticals to Present Phase I Data for QPI-1002 in Delayed Graft Function at American Transplant Congress

May 4th, 2010|

FREMONT, Calif., May 4, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that data from the Phase I QPI-1002 (I5NP) DGF Study (NCT#00802347) will be presented at the 2010 American Transplant Congress, taking place May 1-5 in San Diego, California. QPI-1002, the first systemically administered siRNA drug […]

Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007

March 1st, 2010|

FREMONT, Calif., March 1st, 2010 – Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007. This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic […]

FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

February 16th, 2010|

FREMONT, Calif., February 16, 2010 – Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as “I5NP”), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant […]

Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002

January 5th, 2010|

First Synthetic siRNA Administered Systemically to Humans for the Prophylaxis of Acute Kidney Injury and Delayed Graft Function

FREMONT, Calif., Jan. 5  Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board (“DSMB”) recommended that QPI-1002 (I5NP) continue on to the next phase of clinical […]

Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials

November 19th, 2009|

With IND Now Open, Fifth Clinical Study, in Ocular Neuroprotection, Set to Begin in 1Q10

Fremont, CA – November 19, 2009 – Quark Pharmaceuticals, Inc., the leader in siRNA therapeutics in clinicals, announced today that four of its siRNA R&D platform based programs have met clinical development milestones; patient enrollment was completed in three clinical studies […]

Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases

November 2nd, 2009|

Fremont, CA – November 2, 2009 – Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the […]